Brokerages expect Integra Lifesciences Holdings Corp (NASDAQ:IART) to announce earnings of $0.62 per share for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Integra Lifesciences’ earnings. The highest EPS estimate is $0.64 and the lowest is $0.59. Integra Lifesciences reported earnings per share of $0.64 in the same quarter last year, which would suggest a negative year over year growth rate of 3.1%. The company is scheduled to issue its next quarterly earnings results on Tuesday, February 26th.
According to Zacks, analysts expect that Integra Lifesciences will report full year earnings of $2.39 per share for the current fiscal year, with EPS estimates ranging from $2.36 to $2.41. For the next fiscal year, analysts anticipate that the firm will report earnings of $2.66 per share, with EPS estimates ranging from $2.61 to $2.71. Zacks’ EPS averages are a mean average based on a survey of research firms that cover Integra Lifesciences.
Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings data on Wednesday, October 31st. The life sciences company reported $0.59 EPS for the quarter, hitting the consensus estimate of $0.59. The business had revenue of $365.85 million for the quarter, compared to analyst estimates of $367.89 million. Integra Lifesciences had a net margin of 5.49% and a return on equity of 16.99%. The company’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.45 earnings per share.
Several brokerages have commented on IART. Zacks Investment Research raised shares of Integra Lifesciences from a “sell” rating to a “hold” rating in a research report on Wednesday. BidaskClub lowered shares of Integra Lifesciences from a “buy” rating to a “hold” rating in a research report on Tuesday. UBS Group began coverage on shares of Integra Lifesciences in a research report on Tuesday, November 27th. They issued a “neutral” rating and a $58.00 price objective on the stock. Citigroup lowered their price objective on shares of Integra Lifesciences from $66.00 to $60.00 and set a “neutral” rating on the stock in a research report on Friday, November 2nd. Finally, JMP Securities lowered their price objective on shares of Integra Lifesciences from $66.00 to $62.00 and set a “market outperform” rating on the stock in a research report on Friday, November 2nd. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and four have assigned a buy rating to the stock. Integra Lifesciences presently has a consensus rating of “Hold” and a consensus price target of $61.62.
Shares of IART stock opened at $49.96 on Friday. The stock has a market capitalization of $4.34 billion, a price-to-earnings ratio of 25.75, a P/E/G ratio of 1.59 and a beta of 0.76. The company has a debt-to-equity ratio of 1.04, a quick ratio of 2.08 and a current ratio of 3.20. Integra Lifesciences has a 52 week low of $45.96 and a 52 week high of $67.50.
In other news, major shareholder Richard E. Caruso sold 46,676 shares of Integra Lifesciences stock in a transaction dated Wednesday, October 17th. The shares were sold at an average price of $63.19, for a total value of $2,949,456.44. Following the completion of the transaction, the insider now owns 134,134 shares in the company, valued at $8,475,927.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Barbara B. Hill bought 3,705 shares of Integra Lifesciences stock in a transaction dated Monday, November 5th. The stock was acquired at an average price of $53.90 per share, with a total value of $199,699.50. Following the purchase, the director now directly owns 63,381 shares of the company’s stock, valued at $3,416,235.90. The disclosure for this purchase can be found here. 5.10% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Clearbridge Investments LLC grew its stake in Integra Lifesciences by 7.9% during the third quarter. Clearbridge Investments LLC now owns 1,810,641 shares of the life sciences company’s stock valued at $119,267,000 after acquiring an additional 132,805 shares in the last quarter. Legal & General Group Plc grew its stake in Integra Lifesciences by 3.1% during the third quarter. Legal & General Group Plc now owns 76,875 shares of the life sciences company’s stock valued at $5,063,000 after acquiring an additional 2,333 shares in the last quarter. Nordea Investment Management AB purchased a new position in Integra Lifesciences during the third quarter valued at approximately $5,089,000. Koshinski Asset Management Inc. purchased a new position in Integra Lifesciences during the third quarter valued at approximately $201,000. Finally, Sector Gamma AS grew its stake in Integra Lifesciences by 3.7% during the third quarter. Sector Gamma AS now owns 338,733 shares of the life sciences company’s stock valued at $22,312,000 after acquiring an additional 12,074 shares in the last quarter. Hedge funds and other institutional investors own 85.94% of the company’s stock.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
See Also: Asset Allocation and Your Retirement
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.